Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;43(11):2668-2674.
doi: 10.2337/dc20-0701. Epub 2020 Sep 8.

The Pathological Evolution of Glucose Response Curves During the Progression to Type 1 Diabetes in the TrialNet Pathway to Prevention Study

Heba M Ismail  1 , Mario A Cleves  2 , Ping Xu  2 , Ingrid M Libman  3 , Dorothy J Becker  3 , Jennifer B Marks  4 , Jay S Skyler  4 , Jerry P Palmer  5   6 , Jay M Sosenko  4 ; Type 1 Diabetes TrialNet Study Group
Affiliations

The Pathological Evolution of Glucose Response Curves During the Progression to Type 1 Diabetes in the TrialNet Pathway to Prevention Study

Heba M Ismail et al. Diabetes Care. 2020 Nov.

Abstract

Objective: Glucose response curves (GRCs) during oral glucose tolerance tests (OGTTs) are predictive of type 1 diabetes. We performed a longitudinal analysis in pancreatic autoantibody-positive individuals to assess 1) characteristic GRC changes during progression to type 1 diabetes and 2) GRC changes in relation to β-cell function changes and to combined glucose and C-peptide response curve (GCRC) changes.

Research design and methods: Among antibody-positive individuals with serial OGTTs in the TrialNet Pathway to Prevention study, GRC changes from first to last OGTTs were compared between progressors (n = 298) to type 1 diabetes and nonprogressors (n = 2,216). GRC changes from last OGTT before diagnosis to diagnostic OGTTs were studied in progressors.

Results: GRCs changed more frequently from biphasic (two peaks) to monophasic (one peak) GRCs between first and last OGTTs in progressors than in nonprogressors (75.4% vs. 51.0%, respectively; P < 0.001). In contrast, GRCs of progressors changed less frequently from monophasic to biphasic than those of nonprogressors (12.6% vs. 30.6%; P < 0.001). Monotonic (continuous increase) GRCs were present in 47.7% of progressors at diagnosis. The early (30-0 min) C-peptide response decreased in progressors with GRCs changing from biphasic to monophasic between first and last OGTTs (P < 0.001) and from monophasic to monotonic between last and diagnostic OGTTs (P < 0.001). Conversely, the early C-peptide response increased among nonprogressors with GRCs changing from monophasic to biphasic (P < 0.001). Changes in GRCs were related to changes in GCRCs.

Conclusions: Characteristic GRC changes, biphasic to monophasic to monotonic, occur during the progression to type 1 diabetes. These GRC changes correspond to decreasing β-cell function.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Change in GRC shape over time from first to last OGTT among progressors and nonprogressors. Progressors (change from first to last, n = 298): P = 0.043. Nonprogressors (change from first to last, n = 2,216): P < 0.001.
Figure 2
Figure 2
Change in GRC shapes, among progressors who had a diagnostic OGTT for comparison (n = 153), from first to last OGTT and from last OGTT prior to diagnosis to diagnostic OGTT (Dx OGTT). P value <0.001 for the difference in distribution of the GRC shape at each time point.
Figure 3
Figure 3
Two-dimensional grids (glucose on the y-axis and C-peptide on the x-axis) showing the GCRCs from 30 to 120 min and their centroid comparisons (comparison of the central location for each plot) for nonprogressors with GRCs that changed from monophasic to biphasic from first to last OGTT (A), progressors with GRCs that changed from monophasic to monotonic from last to diagnostic OGTTs (B), and progressors with GRCs that remained monophasic from last to diagnostic OGTTs (C). Arrows in each panel point to the change in location of the centroid locations on the grid. *Mean values for glucose and C-peptide at the different time points (30–120 min) during the OGTT.
See this image and copyright information in PMC

References

    1. Ismail HM, Xu P, Libman IM, et al. .; Type 1 Diabetes TrialNet Study Group . The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes. Diabetologia 2018;61:84–92 - PMC - PubMed
    1. Tschritter O, Fritsche A, Shirkavand F, Machicao F, Häring H, Stumvoll M. Assessing the shape of the glucose curve during an oral glucose tolerance test. Diabetes Care 2003;26:1026–1033 - PubMed
    1. Kanauchi M, Kimura K, Kanauchi K, Saito Y. Beta-cell function and insulin sensitivity contribute to the shape of plasma glucose curve during an oral glucose tolerance test in non-diabetic individuals. Int J Clin Pract 2005;59:427–432 - PubMed
    1. Trujillo-Arriaga HM, Román-Ramos R. Fitting and evaluating the glucose curve during a quasi continuous sampled oral glucose tolerance test. Comput Biol Med 2008;38:185–195 - PubMed
    1. Abdul-Ghani MA, Lyssenko V, Tuomi T, Defronzo RA, Groop L. The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes. Diabetes Metab Res Rev 2010;26:280–286 - PubMed

Publication types

MeSH terms